Norwood  MA   Sept 26  2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings  Inc (NASDAQ: CRBP) ("Corbus" or the "Company")  a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates  announced today that Yuval Cohen  Ph